Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov 14;45(11):977-981.
doi: 10.3760/cma.j.cn121090-20240817-00308.

[Allogeneic hematopoietic stem cell transplantation during the normalization stage of COVID-19 management]

[Article in Chinese]
Q F Liu  1 , R Lin  1
Affiliations

[Allogeneic hematopoietic stem cell transplantation during the normalization stage of COVID-19 management]

[Article in Chinese]
Q F Liu et al. Zhonghua Xue Ye Xue Za Zhi. .

Abstract
in English, Chinese

At present, the world has entered the normalization stage of coronavirus disease 2019 (COVID-19) management. COVID-19 continues to affect patients with allogeneic hematopoietic stem cell transplantation (allo-HSCT) for a long period. The author discussed the possible effect of COVID-19 on HSCT strategy and prognosis during this period based on literature reports. Transplantation should be deferred until clinical resolution and negative severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients infected with SARS-CoV-2 before transplantation. Donors infected with SARS-CoV-2 during the stem cell collection may not affect apheresis. Allo-HSCT recipients demonstrated a high rate of severe COVID-19 if COVID-19 occurred at the early stage of transplantation. Severe COVID-19 remains a risk factor for nonrelapse mortality and survival after transplantation. The association between COVID-19 and post-transplantation complications, such as other infections, endothelial injury-related complications, and relapse, needs to be further investigated in large samples.

目前全球已经进入新型冠状病毒肺炎（COVID-19）疫情防控常态化阶段。COVID-19仍将在较长时间内影响异基因造血干细胞移植（allo-HSCT）患者，作者探讨现阶段COVID-19对allo-HSCT策略及预后的可能影响。移植前感染SARS-CoV-2的患者移植时机选择在症状缓解且SARS-CoV-2转阴后为优。供者采集时感染或并不影响采集。allo-HSCT患者移植早期发生COVID-19仍有较高的重症发生率；重症COVID-19仍然是移植后非复发死亡和生存的危险因素。COVID-19与移植后并发症如其他感染、内皮损伤相关并发症及复发的关系有待进一步大样本研究。.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. Majhail NS, De Lima M. Transplantation and Cellular Therapy. In: Aljurf M, Majhail NS, Koh MBC, et al., editors. The Comprehensive Cancer Center: Development, Integration, and Implementation[M] Cham (CH): Springer; 2022. pp. 121–133. - PubMed
    1. Cesaro S, Mikulska M, Hirsch HH, et al. Update of recommendations for the management of COVID-19 in patients with haematological malignancies, haematopoietic cell transplantation and CAR T therapy, from the 2022 European Conference on Infections in Leukaemia (ECIL 9)[J] Leukemia. 2023;37(9):1933–1938. doi: 10.1038/s41375-023-01938-5. - DOI - PMC - PubMed
    1. Krajewski J, Chen J, Motiani J, et al. Hematopoietic stem cell transplant in two pediatric patients testing positive for SARS-CoV-2: A case report[J] Pediatr Transplant. 2022;26(2):e14179. doi: 10.1111/petr.14179. - DOI - PMC - PubMed
    1. Oltolini C, Acerbis A, Orofino G, et al. Case Report: Favorable outcome of allogeneic hematopoietic stem cell transplantation in SARSCoV2 positive recipient, risk-benefit balance between infection and leukemia[J] Front Immunol. 2023;14:1184956. doi: 10.3389/fimmu.2023.1184956. - DOI - PMC - PubMed
    1. 林 凡, 孙 慧, 陈 瑶, et al. 新型冠状病毒感染对造血干细胞移植供者采集物组分以及早期疗效的影响[J] 中华血液学杂志. 2023;44(11):890–899. doi: 10.3760/cma.j.issn.0253-2727.2023.11.002. - DOI
    2. Lin F, Sun H, Chen Y, et al. Impact of SARS-CoV-2 infection on graft composition and early transplant outcomes following allogeneic hematopoietic stem cell transplantation[J] Chin J Hematol. 2023;44(11):890–899. doi: 10.3760/cma.j.issn.0253-2727.2023.11.002. - DOI - PMC - PubMed

Publication types